1
|
Zheng H, Cheng ZJ, Liang B, Wang ZG, Tao YP, Huang SY, Ni JS, Li HF, Yang L, Yuan SX, Wu J, Kawaguchi T, Samant H, Zhou WP, Xiang DM, Yang Y. N 6-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis. Int J Biol Sci 2023; 19:1009-1023. [PMID: 36923927 PMCID: PMC10008695 DOI: 10.7150/ijbs.73570] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Accepted: 12/28/2022] [Indexed: 02/04/2023] Open
Abstract
Bones are categorized as the second most prevalent location of extra-hepatic metastasis in Hepatocellular Carcinoma (HCC), which is linked to an extremely poor prognosis due to limited therapeutic options. N6-methyladenosine (m6A) is a prominent modification involved in HCC, but the exact mechanisms on how m6A modifications induce HCC bone metastases (BM) remain unclear. The key modulators responsible for the abundant m6A RNA modification-induced HCC BM was found to be the METTL3 and YTHDF1. The expression of Anillin actin-binding protein (ANLN) was dramatically higher in HCC with BM tissues, and its messenger RNA (mRNA) stability was enhanced via m6A epitranscriptomic regulation by METTL3 and YTHDF1. High METTL3 and YTHDF1 expression along with nuclear ANLN protein was clinically correlated with BM in HCC patients. Furthermore, HCC BM was attributed to over-expression of nuclear ANLN forming a transcriptional complex with SP1 which enhanced KIF2C transcriptional activity to activate the mTORC1 pathway, therefore increased the expression of RANKL and disproportionated RANKL-OPG expression in bone microenvironment leading to malignant neoplasms invade bone tissue. In addition, inhibition of ANLN m6A modification by DZNeP attenuated HCC BM. This data provides meaningful understanding of the modulation and association of m6A epitranscriptomic-regulated BM in HCC, and moreover, defines potentially valuable therapeutic targets.
Collapse
Affiliation(s)
- Hao Zheng
- Third Department of Hepatic Surgery, Third Affiliated Hospital, Naval Medical University, Shanghai 200438, China.,Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Zhang-Jun Cheng
- Department of Hepato-Pancreato-Biliary Centers, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing 210009, China
| | - Bo Liang
- Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China
| | - Zhen-Guang Wang
- Third Department of Hepatic Surgery, Third Affiliated Hospital, Naval Medical University, Shanghai 200438, China.,Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Yuan-Ping Tao
- Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Sheng-Yu Huang
- Department of Hepatobiliary and Pancreatic Surgery, The 10th People's Hospital, Tongji University, Shanghai 200433, China
| | - Jun-Sheng Ni
- Third Department of Hepatic Surgery, Third Affiliated Hospital, Naval Medical University, Shanghai 200438, China.,Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Hui-Fen Li
- Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Le Yang
- Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Sheng-Xian Yuan
- Third Department of Hepatic Surgery, Third Affiliated Hospital, Naval Medical University, Shanghai 200438, China.,Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Jennifer Wu
- Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
| | - Takumi Kawaguchi
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
| | - Hrishikesh Samant
- Hrishikesh Samant, Division of Gastroenterology and Hepatology, LSU Health Science Center, Shreveport, LA, USA
| | - Wei-Ping Zhou
- Third Department of Hepatic Surgery, Third Affiliated Hospital, Naval Medical University, Shanghai 200438, China.,Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| | - Dai-Min Xiang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
| | - Yuan Yang
- Third Department of Hepatic Surgery, Third Affiliated Hospital, Naval Medical University, Shanghai 200438, China.,Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai 200438, China.,Department of Organization Sample Bank, Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, China
| |
Collapse
|
2
|
Abstract
Anillin actin binding protein (ANLN) is a biomarker of cancer progression and is overexpressed in lung adenocarcinoma. The aim of the present study was to investigate the role of ANLN protein and RNA in the development of lung adenocarcinoma. The ANLN protein sequence was downloaded from The National Centre for Biotechnology information, RNA sequencing (RNA-seq) data was obtained from The Cancer Genome Atlas database. All immunohistochemical staining pictures were adapted from the Human Protein Atlas. PyMOL software was employed to predict protein functional changes in response to mutations. Gene Set Enrichments Analysis was employed for pathway analysis. The results indicated that ANLN experiences genetic change and overexpression at the RNA and protein levels in patients with lung adenocarcinoma. Kaplan-Meier survival curve analysis revealed significant differences between high and low RNA-seq expression levels in ANLN, and patients exhibiting higher expression of ANLN had a relatively poor prognosis. Pathway analysis demonstrated that ANLN was involved in developmental processes via the regulation of nuclear division' pathway. In conclusion, ANLN has potential for use as a diagnostic and prognostic biomarker to diagnoseand predict the outcome of lung adenocarcinoma.
Collapse
Affiliation(s)
- Xiangyu Long
- Department of Oncology, West China Guang'an Hospital, Sichuan University, Guang'an, Sichuan 638000, P.R. China
| | - Wei Zhou
- Department of Oncology, West China Guang'an Hospital, Sichuan University, Guang'an, Sichuan 638000, P.R. China
| | - Yuanxing Wang
- Department of Oncology, West China Guang'an Hospital, Sichuan University, Guang'an, Sichuan 638000, P.R. China
| | - Shiqiang Liu
- Department of Cardiothoracic Surgery, Nanchong Central Hospital, The Second Clinical College of North Sichuan Medical College, Nanchong, Sichuan 637900, P.R. China
| |
Collapse
|